Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $181.79M.
ENTERPRISE VALUE (EV)
$181.79M
Karyopharm Therapeutics Inc.
Market Cap
$15.43M
Enterprise Value (EV)
$181.79M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $15.43M | $181.79M |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.95M | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | $14.59M |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.51M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | $21.06M |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | $11.31M |
| BioCardia, Inc. (BCDA)vs › | $16.07M | $12.25M |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.89M | $4.06M |
| IN8bio, Inc. (INAB)vs › | $13.89M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | $5.85M |
Market Cap
$15.43M
Total Debt
$226.90M
Cash
$60.54M
Enterprise Value
$181.79M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
